Clinical Trial Detail

NCT ID NCT02399371
Title Pembrolizumab in Treating Patients With Malignant Mesothelioma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications

malignant pleural mesothelioma

peritoneal mesothelioma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.